Dashlabs.ai
-67%
est. 2Y upside i
Software for medical laboratories and clinics
Rank
#1188
Sector
HealthTech
Est. Liquidity
~4Y
Data Quality
Data: MediumDashlabs.ai presents a moderate upside opportunity driven by its niche in emerging market healthcare IT with AI, but job seekers should weigh this against the inherent risks of an early-stage company operating in a competitive, regulated sector.
Last updated: February 16, 2026
Significant expansion in emerging markets, successful AI integration, and strategic partnerships lead to a strong acquisition or a successful Series B/C round.
Continued steady growth in the Philippines, maintaining its niche, leading to a modest Series B or a smaller acquisition within 3-5 years.
Intense competition, regulatory hurdles, or inability to scale effectively leads to a down round, failure to secure further funding, or a distressed acquisition.
Community
Valuation Sentiment
Our model estimates -67% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.